Developer docs
API playgroundTry for free, no card

Search company profiles

Topos Bio

Full company profile

uuid00kda5a

Namestring
Topos Bio
Legal namestring
Topos Bio
Websiteurl
toposbio.ai
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Topos Bio is a privately held, pre-revenue biotechnology company founded in 2025 and headquartered in San Francisco that is building an AI-native drug discovery platform for intrinsically disordered proteins (IDPs). IDPs comprise roughly one-third of the human proteome and lack stable binding pockets, which makes them inaccessible to conventional lock-and-key drug design and traditional static-structure predictors such as AlphaFold. The company was co-founded by Ryan Zarcone, a UC Berkeley-trained biophysicist and former AI lead at Fountain Therapeutics who serves as CEO, and Amir Khosrowshahi, former CTO of Intel AI and co-founder of Nervana (acquired by Intel for $400M).

The core product is the Topos-1 foundation model, an all-atom generative model that produces physically realistic conformational ensembles capturing protein dynamics, generating tens of thousands of conformers in minutes. Topos-1 reportedly outperforms AlphaFold-2, Chai-1, and Boltz-2x on IDP-specific benchmarks (40%+ lower SAXS-derived radius of gyration error, 30%+ lower NMR chemical shift error across 104 IDPs) and runs roughly 1,000x faster than atomistic molecular dynamics. The platform integrates this modeling layer with a generative chemistry pipeline for small-molecule design and an in-house wet lab for experimental validation, creating a flywheel in which experimental data refines the model. The proprietary IDP-focused training dataset, combining physics-based simulations with internal measurements, is positioned as a durable data advantage.

The business model is structured around licensing and co-development of therapeutic candidates rather than platform SaaS or services revenue. Initial therapeutic programs focus on neurodegenerative disorders (Alzheimer's, Parkinson's via alpha-synuclein in partnership with Gladstone Institutes), with oncology (prostate cancer) and metabolic diseases as subsequent verticals. The company has raised $10.5M in seed funding (January 2026) led by Boldstart Ventures, Threshold Ventures, and Neo, with angels including Dara Khosrowshahi and Naveen Rao, and has added Dalriada Drug Discovery as a proteomics and mass spectrometry validation partner.

Short descriptiontext

Topos Bio is a San Francisco-based, pre-revenue AI-native biotechnology company developing the Topos-1 foundation model and drug discovery platform to design small molecules against intrinsically disordered proteins implicated in neurodegenerative disease, oncology, and metabolic disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, computational biology, intrinsically disordered proteins, foundation model, generative chemistry
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
AI Drug Discovery
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Development and Licensing
TypeLicensing Royalties
Description

Pre-revenue company developing AI-driven therapeutics for intrinsically disordered proteins. Revenue model will likely involve licensing drug candidates to pharmaceutical partners, co-development agreements, or eventual product commercialization. Initial therapeutic programs focus on neurodegenerative disorders (Alzheimer's, Parkinson's) followed by oncology and metabolic diseases.

toposbio.ai
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Topos-1
Description

All-atom foundation model for intrinsically disordered proteins that generates physically realistic conformational ensembles for flexible proteins at high speed, enabling ensemble-level modeling for drug discovery and research applications.

toposbio.ai
Core offering1 text field

Topos Bio builds an AI-native integrated drug discovery platform that combines the Topos-1 all-atom foundation model with generative chemistry and wet lab validation to design small-molecule therapeutics against intrinsically disordered proteins (IDPs). The platform models IDPs as dynamic conformational ensembles rather than static structures, enabling rational drug design for targets previously considered "undruggable" in neurodegenerative diseases, oncology, and metabolic disorders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Topos-1 reduces normalized radius of gyration error by at least 40% compared to leading structure prediction models (BioEmu, Chai-1, Boltz-2x, AlphaFold-2) across 104 IDPs
+3 more records
Product overview1 text field

Topos Bio is an AI-native drug discovery company offering an integrated platform that combines the Topos-1 foundation model with generative chemistry and wet lab validation. Topos-1 generates all-atom conformational ensembles for intrinsically disordered proteins (IDPs), capturing their dynamic behavior that traditional static structure predictors miss. The platform then uses these ensembles to identify binding opportunities and design small molecule drug candidates, with an integrated wet lab for experimental validation. The company focuses on neurodegenerative disorders (Alzheimer's, Parkinson's), oncology (prostate cancer), and metabolic diseases as initial therapeutic areas.

Product and service2 records
1Topos Bio AI Drug Discovery Platform
CategoryAI Drug Discovery Platform
Description

AI-native integrated drug discovery platform that models intrinsically disordered proteins (IDPs) as dynamic conformational ensembles rather than static structures, enabling rational drug design for targets previously considered undruggable. Combines the Topos-1 foundation model with generative chemistry capabilities and integrated wet lab validation for pharmaceutical and biotech partners.

2Topos-1 Foundation Model
CategoryAI Foundation Model
Description

All-atom foundation model purpose-built for intrinsically disordered proteins (IDPs) that generates physically realistic conformational ensembles at approximately 1,000x the speed of atomistic molecular dynamics. Outperforms AlphaFold, Chai-1, and Boltz-2x by 40%+ on SAXS radius of gyration error and 30%+ on NMR chemical shift error across 104 IDPs. Trained on a proprietary dataset combining large-scale physics-based simulations and internal experimental measurements specifically designed for IDPs.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-17
Description

Research collaboration to accelerate experimental validation for intrinsically disordered protein (IDP) drug discovery using advanced protein mass spectrometry and proteomics. Topos Bio leverages Dalriada's infrastructure and iCLASS platform to generate high-resolution data on protein-small molecule interactions to guide iterative drug design and prioritization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Strategic collaboration focused on discovering novel modulators for alpha-synuclein, a disordered protein central to Parkinson's disease pathology. Combines Gladstone's advanced imaging and disease modeling capabilities with Topos Bio's computational methods for translational research in neurodegenerative disease.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Atomwise applies AI (AtomNet) to structure-based small molecule drug design across multiple therapeutic areas. It is a direct peer in AI-driven small-molecule discovery with a similar partnership-heavy GTM model targeting pharma licensing deals.

2Iambic Therapeutics
TypeDirect peer
Description

Iambic (formerly Entasis) develops AI-driven therapeutics using physics-informed neural networks for structure-based design. It is a direct peer applying AI to protein-ligand modeling and small-molecule discovery, with overlapping technology stack in protein dynamics modeling and a comparable early-stage profile.

3CrIA Cubiq (Cradle Bio)
TypeEmerging player
Description

Cradle applies generative AI to protein engineering and biologic design. It is an emerging player in AI-driven protein science that overlaps with Topos Bio's focus on dynamic proteins, though it focuses on engineering novel proteins rather than targeting disordered ones with small molecules.

TypeEmerging player
Description

Generate Biomedicines uses generative AI to design novel protein therapeutics. It is an emerging player in AI-driven biologic design; while focused on de novo proteins rather than IDP-targeted small molecules, it competes for similar AI-bio investor capital and addresses complementary parts of the undruggable-proteome opportunity.

TypeBroad incumbent
Description

XtalPi combines AI, quantum physics, and robotic experimentation for drug discovery and has established major partnerships with global pharma. It is a broad incumbent in AI + physics-based drug discovery with significantly more capital and a more mature commercial footprint than Topos Bio.

TypeDirect peer
Description

Recursion uses AI and high-throughput wet-lab experimentation to discover drugs across multiple therapeutic areas. It is a direct peer in the AI-native drug discovery category, with a more mature pipeline and larger capital base, but overlapping business model of combining computational prediction with experimental validation.

TypeDirect peer
Description

Insitro is a well-capitalized AI-driven drug discovery company combining machine learning with high-throughput biology to develop therapeutics. It is a direct peer to Topos Bio as both apply AI/ML to target identification and small-molecule design, though Insitro's initial focus has been on generative models for chemistry and induced pluripotent stem cell biology rather than IDPs.

TypeBroad incumbent
Description

Schrödinger is a publicly traded computational chemistry and physics-based drug discovery platform with a broad pharma customer base. It is a broad incumbent providing similar physics-based molecular modeling and ensemble-aware simulation capabilities that compete with Topos-1's value proposition for pharma partners.

9Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs is Alphabet's drug discovery spinout applying DeepMind's protein structure prediction advances (AlphaFold) to therapeutic development. It is a broad incumbent in AI-driven structure-based drug discovery, with substantially greater resources and competing approaches to the same undruggable-target problem Topos Bio addresses.

TypeOthers
Description

DeepMind developed AlphaFold, the leading static protein structure predictor against which Topos-1 benchmarks. Although not a direct commercial competitor, DeepMind's open releases set the technical baseline for AI protein modeling and indirectly constrain the commercial defensibility of any AI protein discovery platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Topos Bio

AI Drug Discoverytoposbio.ai

Topos Bio is a San Francisco-based, pre-revenue AI-native biotechnology company developing the Topos-1 foundation model and drug discovery platform to design small molecules against intrinsically disordered proteins implicated in neurodegenerative disease, oncology, and metabolic disorders.

What Topos Bio does

Topos Bio is a privately held, pre-revenue biotechnology company founded in 2025 and headquartered in San Francisco that is building an AI-native drug discovery platform for intrinsically disordered proteins (IDPs). IDPs comprise roughly one-third of the human proteome and lack stable binding pockets, which makes them inaccessible to conventional lock-and-key drug design and traditional static-structure predictors such as AlphaFold. The company was co-founded by Ryan Zarcone, a UC Berkeley-trained biophysicist and former AI lead at Fountain Therapeutics who serves as CEO, and Amir Khosrowshahi, former CTO of Intel AI and co-founder of Nervana (acquired by Intel for $400M).

The core product is the Topos-1 foundation model, an all-atom generative model that produces physically realistic conformational ensembles capturing protein dynamics, generating tens of thousands of conformers in minutes. Topos-1 reportedly outperforms AlphaFold-2, Chai-1, and Boltz-2x on IDP-specific benchmarks (40%+ lower SAXS-derived radius of gyration error, 30%+ lower NMR chemical shift error across 104 IDPs) and runs roughly 1,000x faster than atomistic molecular dynamics. The platform integrates this modeling layer with a generative chemistry pipeline for small-molecule design and an in-house wet lab for experimental validation, creating a flywheel in which experimental data refines the model. The proprietary IDP-focused training dataset, combining physics-based simulations with internal measurements, is positioned as a durable data advantage.

The business model is structured around licensing and co-development of therapeutic candidates rather than platform SaaS or services revenue. Initial therapeutic programs focus on neurodegenerative disorders (Alzheimer's, Parkinson's via alpha-synuclein in partnership with Gladstone Institutes), with oncology (prostate cancer) and metabolic diseases as subsequent verticals. The company has raised $10.5M in seed funding (January 2026) led by Boldstart Ventures, Threshold Ventures, and Neo, with angels including Dara Khosrowshahi and Naveen Rao, and has added Dalriada Drug Discovery as a proteomics and mass spectrometry validation partner.

Topos Bio firmographics

Firmographics
Name
Topos Bio
Legal name
Topos Bio
Website
https://toposbio.ai
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Short description
Topos Bio is a San Francisco-based, pre-revenue AI-native biotechnology company developing the Topos-1 foundation model and drug discovery platform to design small molecules against intrinsically disordered proteins implicated in neurodegenerative disease, oncology, and metabolic disorders.
Ownership category
akta.pro rank

Topos Bio industry classification

Industry
Product category
AI Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Computational biology
  • Intrinsically disordered proteins
  • Foundation model
  • Generative chemistry

Where Topos Bio is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Topos Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Therapeutic Development and Licensing: Pre-revenue company developing AI-driven therapeutics for intrinsically disordered proteins. Revenue model will likely involve licensing drug candidates to pharmaceutical partners, co-development agreements, or eventual product commercialization. Initial therapeutic programs focus on neurodegenerative disorders (Alzheimer's, Parkinson's) followed by oncology and metabolic diseases.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Topos Bio product offering

Product offering

Core offering

Topos Bio builds an AI-native integrated drug discovery platform that combines the Topos-1 all-atom foundation model with generative chemistry and wet lab validation to design small-molecule therapeutics against intrinsically disordered proteins (IDPs). The platform models IDPs as dynamic conformational ensembles rather than static structures, enabling rational drug design for targets previously considered "undruggable" in neurodegenerative diseases, oncology, and metabolic disorders.

Product overview

Topos Bio is an AI-native drug discovery company offering an integrated platform that combines the Topos-1 foundation model with generative chemistry and wet lab validation. Topos-1 generates all-atom conformational ensembles for intrinsically disordered proteins (IDPs), capturing their dynamic behavior that traditional static structure predictors miss. The platform then uses these ensembles to identify binding opportunities and design small molecule drug candidates, with an integrated wet lab for experimental validation. The company focuses on neurodegenerative disorders (Alzheimer's, Parkinson's), oncology (prostate cancer), and metabolic diseases as initial therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

  • Topos-1: All-atom foundation model for intrinsically disordered proteins that generates physically realistic conformational ensembles for flexible proteins at high speed, enabling ensemble-level modeling for drug discovery and research applications.

Products and services

  • Topos Bio AI Drug Discovery Platform AI-native integrated drug discovery platform that models intrinsically disordered proteins (IDPs) as dynamic conformational ensembles rather than static structures, enabling rational drug design for targets previously considered undruggable. Combines the Topos-1 foundation model with generative chemistry capabilities and integrated wet lab validation for pharmaceutical and biotech partners.
  • Topos-1 Foundation Model All-atom foundation model purpose-built for intrinsically disordered proteins (IDPs) that generates physically realistic conformational ensembles at approximately 1,000x the speed of atomistic molecular dynamics. Outperforms AlphaFold, Chai-1, and Boltz-2x by 40%+ on SAXS radius of gyration error and 30%+ on NMR chemical shift error across 104 IDPs. Trained on a proprietary dataset combining large-scale physics-based simulations and internal experimental measurements specifically designed for IDPs.

Quantifiable outcome

  • Topos-1 reduces normalized radius of gyration error by at least 40% compared to leading structure prediction models (BioEmu, Chai-1, Boltz-2x, AlphaFold-2) across 104 IDPs
  • +3 more outcomes

Companies that use Topos Bio

Customer profile

Segments3 records

Ideal customer profiles3 records

Topos Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Topos Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Dalriada Drug DiscoverycoreTechnology or Integration · 17 March 2026Research collaboration to accelerate experimental validation for intrinsically disordered protein (IDP) drug discovery using advanced protein mass spectrometry and proteomics. Topos Bio leverages Dalriada's infrastructure and iCLASS platform to generate high-resolution data on protein-small molecule interactions to guide iterative drug design and prioritization.
  • Gladstone InstitutescoreStrategic or Co-development Partner · 8 January 2026Strategic collaboration focused on discovering novel modulators for alpha-synuclein, a disordered protein central to Parkinson's disease pathology. Combines Gladstone's advanced imaging and disease modeling capabilities with Topos Bio's computational methods for translational research in neurodegenerative disease.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Topos Bio competitors and assessment

Company assessment

Direct peers

  • Atomwise: Atomwise applies AI (AtomNet) to structure-based small molecule drug design across multiple therapeutic areas. It is a direct peer in AI-driven small-molecule discovery with a similar partnership-heavy GTM model targeting pharma licensing deals.
  • Iambic Therapeutics: Iambic (formerly Entasis) develops AI-driven therapeutics using physics-informed neural networks for structure-based design. It is a direct peer applying AI to protein-ligand modeling and small-molecule discovery, with overlapping technology stack in protein dynamics modeling and a comparable early-stage profile.
  • Recursion Pharmaceuticals: Recursion uses AI and high-throughput wet-lab experimentation to discover drugs across multiple therapeutic areas. It is a direct peer in the AI-native drug discovery category, with a more mature pipeline and larger capital base, but overlapping business model of combining computational prediction with experimental validation.
  • Insitro: Insitro is a well-capitalized AI-driven drug discovery company combining machine learning with high-throughput biology to develop therapeutics. It is a direct peer to Topos Bio as both apply AI/ML to target identification and small-molecule design, though Insitro's initial focus has been on generative models for chemistry and induced pluripotent stem cell biology rather than IDPs.

Emerging players

  • CrIA Cubiq (Cradle Bio): Cradle applies generative AI to protein engineering and biologic design. It is an emerging player in AI-driven protein science that overlaps with Topos Bio's focus on dynamic proteins, though it focuses on engineering novel proteins rather than targeting disordered ones with small molecules.
  • Generate Biomedicines: Generate Biomedicines uses generative AI to design novel protein therapeutics. It is an emerging player in AI-driven biologic design; while focused on de novo proteins rather than IDP-targeted small molecules, it competes for similar AI-bio investor capital and addresses complementary parts of the undruggable-proteome opportunity.

Broad incumbents

  • XtalPi: XtalPi combines AI, quantum physics, and robotic experimentation for drug discovery and has established major partnerships with global pharma. It is a broad incumbent in AI + physics-based drug discovery with significantly more capital and a more mature commercial footprint than Topos Bio.
  • Schrödinger: Schrödinger is a publicly traded computational chemistry and physics-based drug discovery platform with a broad pharma customer base. It is a broad incumbent providing similar physics-based molecular modeling and ensemble-aware simulation capabilities that compete with Topos-1's value proposition for pharma partners.
  • Isomorphic Labs: Isomorphic Labs is Alphabet's drug discovery spinout applying DeepMind's protein structure prediction advances (AlphaFold) to therapeutic development. It is a broad incumbent in AI-driven structure-based drug discovery, with substantially greater resources and competing approaches to the same undruggable-target problem Topos Bio addresses.

Others

  • DeepMind (AlphaFold): DeepMind developed AlphaFold, the leading static protein structure predictor against which Topos-1 benchmarks. Although not a direct commercial competitor, DeepMind's open releases set the technical baseline for AI protein modeling and indirectly constrain the commercial defensibility of any AI protein discovery platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Topos Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Topos Bio leadership team

Management profile

Number of profiles

Profiles2 records

Topos Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Topos Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Topos Bio

What does Topos Bio do?

Topos Bio builds an AI-native integrated drug discovery platform that combines the Topos-1 all-atom foundation model with generative chemistry and wet lab validation to design small-molecule therapeutics against intrinsically disordered proteins (IDPs). The platform models IDPs as dynamic conformational ensembles rather than static structures, enabling rational drug design for targets previously considered "undruggable" in neurodegenerative diseases, oncology, and metabolic disorders.

Is Topos Bio a public or private company?

Topos Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Topos Bio founded?

Topos Bio was founded in 2025. It employs 11 to 50 people.

Where is Topos Bio based?

Topos Bio is headquartered in San Francisco, United States, in the North America region.

How does Topos Bio make money?

One revenue line is on record: therapeutic Development and Licensing.

Who are Topos Bio's main competitors?

Direct peers on record are Atomwise, Iambic Therapeutics, Recursion Pharmaceuticals and Insitro. Emerging players are CrIA Cubiq (Cradle Bio) and Generate Biomedicines. Broad incumbents are XtalPi, Schrödinger and Isomorphic Labs. DeepMind (AlphaFold) is listed as an others.

Does Topos Bio have an API?

No public API is recorded for Topos Bio.

What industry is Topos Bio in?

Topos Bio's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceTopos Bio Introduces Topos-2 and Topos-Bind to Combat “Undruggable” DiseasesTopos Bio introduced Topos-2 and Topos-Bind, AI models for intrinsically disordered proteins and their drug interactions. Topos-2 ranked first on PeptoneBench, nearly 4x closer to experimental data than the next-best model, and Topos-Bind predicted amyloid-beta shape changes. The models are being applied to neurodegeneration and oncology programs.PR NewswireDalriada Drug Discovery and Topos Bio Announce Collaboration to Advance Drug Discovery for Intrinsically Disordered ProteinsDalriada Drug Discovery and Topos Bio announced a research collaboration on March 17, 2026, to accelerate drug discovery for intrinsically disordered proteins using advanced protein mass spectrometry and proteomics. Under the agreement, Topos will leverage Dalriada's infrastructure, including the proprietary iCLASS platform, to generate high-resolution data on protein-small molecule interactions for targets that lack stable structure and are difficult to interrogate with conventional approaches. Intrinsically disordered proteins are estimated to comprise approximately 30–40% of the human proteome and are implicated in numerous diseases including neurodegeneration and cancer.MorningstarDalriada Drug Discovery and Topos Bio Announce Collaboration to Advance Drug Discovery for Intrinsically Disordered ProteinsDalriada Drug Discovery and Topos Bio announced a research collaboration to accelerate experimental validation for intrinsically disordered protein (IDP) drug discovery using advanced protein mass spectrometry and proteomics. Under the agreement, Topos will leverage Dalriada's infrastructure and the iCLASS platform to generate high-resolution data on protein-small molecule interactions to guide iterative drug design and prioritization. IDPs are estimated to comprise 30-40% of the human proteome and are implicated in numerous diseases including neurodegeneration and cancer.HLTHTopos Bio Raises $10.5M Seed to Target ‘Undruggable’ Proteins in Alzheimer’s and CancerTopos Bio has emerged from stealth with $10.5 million in seed financing led by Boldstart, Threshold, and Neo to advance an AI-native drug discovery platform targeting intrinsically disordered proteins, a class of biological targets long considered inaccessible to conventional therapeutics. The platform models protein dynamics as ensembles rather than static structures, enabling rational drug design for proteins implicated in Alzheimer’s disease, Parkinson’s disease, and aggressive cancers. Alongside the funding, the company released its Topos-1 foundation model and established a collaboration with Gladstone Institutes focused on alpha-synuclein.